Benzinga | Jan 20, 2022 06:26AM EST

Bristol Myers Squibb Receives Approval For Abecma, The First CAR T Therapy Approved For The Treatment Of Multiple Myeloma In Japan

https://news.bms.com/news/corporate-financial/2022/Bristol-Myers-Squibb-Receives-Approval-for-Abecma-idecabtagene-vicleucel-the-First-CAR-T-Therapy-Approved-for-the-Treatment-of-Multiple-Myeloma-in-Japan/default.aspx